skip to Main Content

Nivolumab/Cabiralizumab Combo Misses PFS Endpoint in Pancreatic Cancer

Nivolumab/Cabiralizumab Combo Misses PFS Endpoint in Pancreatic Cancer
The combination of nivolumab (Opdivo) and the investigational CSF-1R inhibitor cabiralizumab with and without chemotherapy did not improve progression-free survival (PFS) compared with chemotherapy alone in patients with advanced pancreatic cancer, missing the primary endpoint of a phase II trial (NCT03336216).1

Additionally, no new safety signals were observed in the study. Five Prime Therapeutics, the developer of cabiralizumab, stated in a press release that Bristol-Myers Squibb (BMS), the company manufacturing nivolumab, has no near-term plans for additional sponsored development of cabiralizumab.  Read more . . .


Back To Top